Equities Analysts Offer Predictions for STERIS Q4 Earnings

Key Points

• Zacks Research has boosted its earnings per share (EPS) estimate for STERIS's Q4 2026 from $2.85 to $2.86, with the full-year estimate now at $9.08 per share.
• The company recently increased its quarterly dividend to $0.63 per share, marking a growth from the previous $0.57, resulting in an annualized dividend yield of 1.0%.
• STERIS's stock has received multiple upgrades, including a rating change from "buy" to "strong-buy" by Wall Street Zen, and analysts have set an average price target of $273.50 for the stock.

STERIS plc (NYSE:STE - Free Report) - Equities researchers at Zacks Research boosted their Q4 2026 earnings per share (EPS) estimates for STERIS in a research note issued on Tuesday, October 21st. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings of $2.86 per share for the quarter, up from their prior estimate of $2.85. The consensus estimate for STERIS's current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS's Q1 2027 earnings at $2.47 EPS and Q2 2028 earnings at $3.08 EPS.

A number of other research firms have also commented on STE. Weiss Ratings reissued a "buy (b)" rating on shares of STERIS in a research note on Tuesday, October 14th. KeyCorp upped their price target on STERIS from $277.00 to $288.00 and gave the company an "overweight" rating in a research note on Tuesday, July 22nd. Morgan Stanley lifted their price objective on STERIS from $276.00 to $295.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of STERIS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 14th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $273.50.

STERIS Price Performance

STERIS stock opened at $242.29 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The firm has a market cap of $23.86 billion, a P/E ratio of 37.10 and a beta of 1.01. The business's fifty day moving average is $244.96 and its two-hundred day moving average is $236.71. STERIS has a 52 week low of $200.98 and a 52 week high of $253.00.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.32 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business's revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.03 earnings per share.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 26th. Stockholders of record on Thursday, September 4th were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, September 4th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. This is an increase from STERIS's previous quarterly dividend of $0.57. STERIS's dividend payout ratio is presently 38.59%.

Insider Activity at STERIS

In other news, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $241.82, for a total transaction of $38,449.38. Following the completion of the transaction, the chief executive officer directly owned 51,096 shares in the company, valued at approximately $12,356,034.72. The trade was a 0.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mohsen Sohi sold 4,110 shares of STERIS stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $241.96, for a total value of $994,455.60. Following the transaction, the director owned 22,361 shares of the company's stock, valued at $5,410,467.56. This represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,868 shares of company stock worth $4,585,389 in the last three months. 1.07% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in STE. Geneos Wealth Management Inc. lifted its holdings in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Spurstone Advisory Services LLC acquired a new stake in STERIS during the 2nd quarter worth approximately $29,000. Zions Bancorporation National Association UT acquired a new stake in STERIS during the 1st quarter worth approximately $37,000. TruNorth Capital Management LLC acquired a new stake in STERIS during the 3rd quarter worth approximately $37,000. Finally, Golden State Wealth Management LLC lifted its holdings in STERIS by 503.0% during the 1st quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 166 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.